Anticoagulation therapy for cardioembolic stroke prevention in the elderly

Defining benefits and risks

William D. Freeman, Maria Aguilar

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The number of elderly patients aged 65 years and over has increased over the last 100 years owing to improvements in antisepsis, clean water/sanitation and preventive health strategies. As a result, more people are living longer than in the past and more people require healthcare at an older age. Atrial fibrillation increases with advancing age and is an independent risk factor for cardioembolic stroke. Warfarin anticoagulation has proven to be superior to antiplatelet agents in reducing stroke in high-risk atrial fibrillation patients in several trials. However, owing to potentially harmful or fatal bleeding risks, namely gastrointestinal and intracranial hemorrhage, anticoagulation remains underutilized even in patients in whom the benefit outweighs the risk. The incidence of intracranial hemorrhage during carefully managed warfarin anticoagulation is approximately 0.4-1% annually, but is higher in patients older than 85 years of age, and in patients with supratherapeutic levels of anticoagulation (i.e., international normalized ratio >3.5), whereas gastrointestinal bleeding occurs in approximately 2.5% of patients. Many atrial fibrillation patients aged 75 years or older have an annual ischemic stroke risk between 4 and 18% but remain untreated owing to exaggerated fear of hemorrhagic events, despite a clear benefit-to-risk ratio. We review the literature regarding the assessment of cardioembolic ischemic stroke risk in the aging population and relative benefits of warfarin anticoagulation compared with aspirin therapy, as well as the recent trial comparing warfarin against dabigatran, and relative hemorrhagic risks. We review recent literature providing recommendations about improving outpatient anticoagulation therapy and newer MRI data detecting asymptomatic cerebral microbleeds, which may be clues to why some patients have intracranial bleeding during anticoagulation therapy.

Original languageEnglish (US)
Pages (from-to)439-450
Number of pages12
JournalAging Health
Volume6
Issue number4
DOIs
StatePublished - Aug 2010

Fingerprint

Stroke
Warfarin
Atrial Fibrillation
Intracranial Hemorrhages
Therapeutics
Hemorrhage
Antisepsis
Sanitation
International Normalized Ratio
Gastrointestinal Hemorrhage
Platelet Aggregation Inhibitors
Aspirin
Fear
Outpatients
Odds Ratio
Delivery of Health Care
Water
Incidence
Health
Population

Keywords

  • anticoagulation
  • atrial fibrillation
  • cardioembolic stroke
  • elderly

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

Anticoagulation therapy for cardioembolic stroke prevention in the elderly : Defining benefits and risks. / Freeman, William D.; Aguilar, Maria.

In: Aging Health, Vol. 6, No. 4, 08.2010, p. 439-450.

Research output: Contribution to journalArticle

Freeman, William D. ; Aguilar, Maria. / Anticoagulation therapy for cardioembolic stroke prevention in the elderly : Defining benefits and risks. In: Aging Health. 2010 ; Vol. 6, No. 4. pp. 439-450.
@article{9e6f94a7f2964653aaf05be1d4dd8668,
title = "Anticoagulation therapy for cardioembolic stroke prevention in the elderly: Defining benefits and risks",
abstract = "The number of elderly patients aged 65 years and over has increased over the last 100 years owing to improvements in antisepsis, clean water/sanitation and preventive health strategies. As a result, more people are living longer than in the past and more people require healthcare at an older age. Atrial fibrillation increases with advancing age and is an independent risk factor for cardioembolic stroke. Warfarin anticoagulation has proven to be superior to antiplatelet agents in reducing stroke in high-risk atrial fibrillation patients in several trials. However, owing to potentially harmful or fatal bleeding risks, namely gastrointestinal and intracranial hemorrhage, anticoagulation remains underutilized even in patients in whom the benefit outweighs the risk. The incidence of intracranial hemorrhage during carefully managed warfarin anticoagulation is approximately 0.4-1{\%} annually, but is higher in patients older than 85 years of age, and in patients with supratherapeutic levels of anticoagulation (i.e., international normalized ratio >3.5), whereas gastrointestinal bleeding occurs in approximately 2.5{\%} of patients. Many atrial fibrillation patients aged 75 years or older have an annual ischemic stroke risk between 4 and 18{\%} but remain untreated owing to exaggerated fear of hemorrhagic events, despite a clear benefit-to-risk ratio. We review the literature regarding the assessment of cardioembolic ischemic stroke risk in the aging population and relative benefits of warfarin anticoagulation compared with aspirin therapy, as well as the recent trial comparing warfarin against dabigatran, and relative hemorrhagic risks. We review recent literature providing recommendations about improving outpatient anticoagulation therapy and newer MRI data detecting asymptomatic cerebral microbleeds, which may be clues to why some patients have intracranial bleeding during anticoagulation therapy.",
keywords = "anticoagulation, atrial fibrillation, cardioembolic stroke, elderly",
author = "Freeman, {William D.} and Maria Aguilar",
year = "2010",
month = "8",
doi = "10.2217/ahe.10.45",
language = "English (US)",
volume = "6",
pages = "439--450",
journal = "Aging Health",
issn = "1745-509X",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Anticoagulation therapy for cardioembolic stroke prevention in the elderly

T2 - Defining benefits and risks

AU - Freeman, William D.

AU - Aguilar, Maria

PY - 2010/8

Y1 - 2010/8

N2 - The number of elderly patients aged 65 years and over has increased over the last 100 years owing to improvements in antisepsis, clean water/sanitation and preventive health strategies. As a result, more people are living longer than in the past and more people require healthcare at an older age. Atrial fibrillation increases with advancing age and is an independent risk factor for cardioembolic stroke. Warfarin anticoagulation has proven to be superior to antiplatelet agents in reducing stroke in high-risk atrial fibrillation patients in several trials. However, owing to potentially harmful or fatal bleeding risks, namely gastrointestinal and intracranial hemorrhage, anticoagulation remains underutilized even in patients in whom the benefit outweighs the risk. The incidence of intracranial hemorrhage during carefully managed warfarin anticoagulation is approximately 0.4-1% annually, but is higher in patients older than 85 years of age, and in patients with supratherapeutic levels of anticoagulation (i.e., international normalized ratio >3.5), whereas gastrointestinal bleeding occurs in approximately 2.5% of patients. Many atrial fibrillation patients aged 75 years or older have an annual ischemic stroke risk between 4 and 18% but remain untreated owing to exaggerated fear of hemorrhagic events, despite a clear benefit-to-risk ratio. We review the literature regarding the assessment of cardioembolic ischemic stroke risk in the aging population and relative benefits of warfarin anticoagulation compared with aspirin therapy, as well as the recent trial comparing warfarin against dabigatran, and relative hemorrhagic risks. We review recent literature providing recommendations about improving outpatient anticoagulation therapy and newer MRI data detecting asymptomatic cerebral microbleeds, which may be clues to why some patients have intracranial bleeding during anticoagulation therapy.

AB - The number of elderly patients aged 65 years and over has increased over the last 100 years owing to improvements in antisepsis, clean water/sanitation and preventive health strategies. As a result, more people are living longer than in the past and more people require healthcare at an older age. Atrial fibrillation increases with advancing age and is an independent risk factor for cardioembolic stroke. Warfarin anticoagulation has proven to be superior to antiplatelet agents in reducing stroke in high-risk atrial fibrillation patients in several trials. However, owing to potentially harmful or fatal bleeding risks, namely gastrointestinal and intracranial hemorrhage, anticoagulation remains underutilized even in patients in whom the benefit outweighs the risk. The incidence of intracranial hemorrhage during carefully managed warfarin anticoagulation is approximately 0.4-1% annually, but is higher in patients older than 85 years of age, and in patients with supratherapeutic levels of anticoagulation (i.e., international normalized ratio >3.5), whereas gastrointestinal bleeding occurs in approximately 2.5% of patients. Many atrial fibrillation patients aged 75 years or older have an annual ischemic stroke risk between 4 and 18% but remain untreated owing to exaggerated fear of hemorrhagic events, despite a clear benefit-to-risk ratio. We review the literature regarding the assessment of cardioembolic ischemic stroke risk in the aging population and relative benefits of warfarin anticoagulation compared with aspirin therapy, as well as the recent trial comparing warfarin against dabigatran, and relative hemorrhagic risks. We review recent literature providing recommendations about improving outpatient anticoagulation therapy and newer MRI data detecting asymptomatic cerebral microbleeds, which may be clues to why some patients have intracranial bleeding during anticoagulation therapy.

KW - anticoagulation

KW - atrial fibrillation

KW - cardioembolic stroke

KW - elderly

UR - http://www.scopus.com/inward/record.url?scp=77956164483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956164483&partnerID=8YFLogxK

U2 - 10.2217/ahe.10.45

DO - 10.2217/ahe.10.45

M3 - Article

VL - 6

SP - 439

EP - 450

JO - Aging Health

JF - Aging Health

SN - 1745-509X

IS - 4

ER -